Amedisys Stock News

BATON ROUGE, La., March 08, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care services, today announced that Chri

BATON ROUGE, La., March 08, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care services, today announced that Chris

AMED, CACC, and EXPO have been added to the Zacks Rank #5 (Strong Sell) List on March 4, 2022

AMED, CACC, and EXPO have been added to the Zacks Rank #5 (Strong Sell) List on March 4, 2022

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71, compared to year-ago quarter

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ: RVMD ) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71, compared to year-ago quarter EPS of $0.52. The stock has a 52-week-high of $50.88 and a 52-week-low of $18.07. At the end of the last trading period, Revolution Medicines closed at $18.92. According to UBS, the prior rating for Amedisys Inc (NASDAQ: AMED ) was changed from Sell to Neutral. For the fourth quarter, Amedisys had an EPS of $1.18, compared to year-ago quarter EPS of $1.49. At the moment, the stock has a 52-week-high of $292.97 and a 52-week-low of $122.12. Amedisys closed at $160.24 at the end of the last trading period. For Sunstone Hotel Investors Inc (NYSE: SHO ), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. At the moment, the stock has a 52-week-high of $13.91 and a 52-week-low of $9.93. Sunstone Hotel Invts closed at $10.58 at the end of the last trading period. Wedbush upgraded the previous rating for Logitech International SA (NASDAQ: LOGI ) from Neutral to Outperform.

BATON ROUGE, La., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care services, today announced that Chris

BATON ROUGE, La., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care services, today announced that Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer, will present at the Raymond James & Associates’ 43 rd Annual Institutional Investors Conference on Tuesday, March 8, at 11:35 a.m. EST.

BATON ROUGE, La., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care services, today announced that Chris G

Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 1 0 0 Last 3

Analysts have provided the following ratings for Amedisys (NASDAQ: AMED ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 1 0 0 Last 30D 0 3 0 0 0 1M Ago 1 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 0 0 0 In the last 3 months, 6 analysts have offered 12-month price targets for Amedisys. The company has an average price target of $186.67 with a high of $213.00 and a low of $147.00. Below is a summary of how these 6 analysts rated Amedisys over the past 3 months. The greater the number of bullish ratings, the more … Full story available on Benzinga.com

Amedisys <> has stretched its post-earnings gains further on Friday after BMO Capital Markets upgraded the healthcare services firm on the strength of its 2022 outlook and…

Upgrades According to 86 Research, the prior rating for NetEase Inc (NASDAQ:NTES) was changed from Hold to Buy. For the fourth quarter, NetEase had an EPS of $1.56, compared to year-ago quarter EPS o

Amedisys, Inc. (AMED) CEO Paul Kusserow on Q4 2021 Results - Earnings Call Transcript